[ad_1]
Jakarta, IDN Times – The Eijkman Biomolecular Institute has started manufacturing the COVID-19 vaccine for the people of Indonesia. Eijkman’s boss, Professor Amin Soebandrio, said his group was currently continuing to identify which parts of the virus produced the best recombinant proteins.
“Currently, the laboratory research process is targeting a year,” he said when IDN Times contacted him on Tuesday (5/5).
1. Eijkman successfully mapped the genomes of three virus isolates
infectionsemerging.kemkes.go.idAs a start, Eijkman provided genome-related data from the research results to the Global Influenza Data Sharing Initiative (GISAID). He said this was the beginning of finding this innovative COVID-19 vaccine.
The Eijkman Institute has successfully mapped its acid sequence. This is the first step in creating the COVID-19 antivirus for Indonesia.
Using the Next Generation Sequencing Tool (NGS) at Eijkman’s EBLM Lij National Genome Center, at least the LBM Eijkman team managed to map the genomes of three virus isolates from three patients confirmed positive for Covid-19 in Indonesia.
2. Eijkman reports three results of the Whole F genome sequences of the coronavirus
Medical Team of the Emergency Hospital COVID-19 in Wisma Atlet, Kemayoran (Instagram / @ nandamalr) Amin explained that the genome series could show the identity of the origin of the corona virus, whether from the United States, Europe or other regions.
Eijkman reported three results from the Whole F genome sequences of the coronavirus that had been isolated from different patients.
Continue reading the article below
Editor’s picks
“The results have not yet come out because it takes several days to identify them,” he said.
3. The government sets a goal of one year.
uhhospitals.orgAmin further explained that the government did provide a target of up to one year, but that time did not include clinical trials.
“Old clinical trials should be on a small or large scale, wait for the response in a few weeks, how many months cannot be accelerated so that at least the amount can be accelerated, not too much,” he said.
Amin even said that following normal investigation procedures would take 3-5 years to finally be applied to humans.
“If the procedure is normal, the clinical trial can reach 3 to 5 years because it involves thousands of people,” he added.
4. Ten Eijkman researchers work every day.
Instagram @ eijkmaninstituteAmin revealed that there were currently ten people on the team to make the COVID-19 vaccine, but after this first phase, Eijkman would collaborate with several other researchers from outside Eijkman, both from universities and LIPI, etc.
“We work every day, even on Saturdays and Sundays, so be smart at the moment,” he said.
Also read: Corona Photo Hoaks Photo in Hand, although virus size is too small
[ad_2]
